Hideki Hasegawa Selected Research

Monoclonal Antibodies

2/2022	Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2.
1/2022	Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.
4/2016	Severe Fever with Thrombocytopenia Syndrome Virus Antigen Detection Using Monoclonal Antibodies to the Nucleocapsid Protein.
1/2011	Passive immune-prophylaxis against influenza virus infection by the expression of neutralizing anti-hemagglutinin monoclonal antibodies from plasmids.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hideki Hasegawa Research Topics

Disease

80	Infections 01/2023 - 03/2002
42	Human Influenza (Influenza) 11/2023 - 06/2003
21	Virus Diseases (Viral Diseases) 02/2024 - 01/2002
15	COVID-19 10/2023 - 01/2020
9	Pneumonia (Pneumonitis) 01/2023 - 06/2003
6	Neoplasms (Cancer) 06/2021 - 05/2003
6	Lymphoma (Lymphomas) 01/2021 - 10/2004
6	Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated) 01/2021 - 04/2006
5	Severe Fever with Thrombocytopenia Syndrome 02/2024 - 01/2016
5	Inflammation (Inflammations) 01/2023 - 03/2009
5	Body Weight (Weight, Body) 01/2022 - 03/2009
4	Asthma (Bronchial Asthma) 10/2022 - 08/2013
3	Influenza in Birds (Avian Flu) 07/2022 - 01/2013
3	Severe Acute Respiratory Syndrome 01/2022 - 06/2005
3	Leukemia 01/2021 - 12/2010
3	Progressive Multifocal Leukoencephalopathy 01/2020 - 09/2012
3	Encephalitis (Encephalitis, Rasmussen) 02/2017 - 03/2013
3	Acquired Immunodeficiency Syndrome (AIDS) 01/2017 - 06/2012
3	Type 2 Diabetes Mellitus (MODY) 01/2014 - 03/2008
2	Breakthrough Infections 05/2023 - 01/2022
2	Obesity 01/2023 - 03/2008
2	Periodontal Diseases (Periodontal Disease) 01/2023 - 01/2011
2	Coronavirus Infections 01/2020 - 01/2019
2	Anemia 09/2019 - 01/2011
2	Lymphadenitis (Adenitis) 04/2018 - 11/2014
2	Viremia 07/2017 - 01/2014
2	Mpox (monkeypox) 07/2017 - 06/2006
2	Disease Progression 02/2017 - 01/2010
2	Communicable Diseases (Infectious Diseases) 07/2014 - 02/2009
2	Vaccinia 08/2006 - 09/2005
2	Smallpox (Variola) 06/2006 - 09/2005
1	Reinfection 01/2023

Drug/Important Bio-Agent (IBA)

52	VaccinesIBA 11/2023 - 03/2002
22	AntibodiesIBA 02/2024 - 01/2002
21	Immunoglobulin A (IgA)IBA 01/2021 - 01/2002
16	Immunoglobulin G (IgG)IBA 01/2021 - 01/2002
15	Hemagglutinins (Hemagglutinin)IBA 01/2021 - 06/2003
14	Proteins (Proteins, Gene)FDA Link 02/2024 - 04/2006
12	CytokinesIBA 01/2023 - 09/2006
12	AntigensIBA 12/2021 - 08/2003
11	Influenza Vaccines (Influenza Vaccine)FDA Link 11/2023 - 01/2002
11	Antiviral Agents (Antivirals)IBA 01/2023 - 01/2018
8	Secretory Immunoglobulin A (SIgA)IBA 01/2022 - 02/2009
6	Neutralizing AntibodiesIBA 02/2024 - 02/2009
6	ChemokinesIBA 01/2023 - 09/2006
6	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 07/2003
5	RNA (Ribonucleic Acid)IBA 05/2023 - 01/2010
5	baloxavirIBA 01/2023 - 11/2019
5	Inactivated VaccinesIBA 04/2020 - 11/2008
5	Interleukin-6 (Interleukin 6)IBA 01/2017 - 02/2009
4	N-(2-cyanoethylene)urea (BA 1)IBA 01/2023 - 01/2022
4	N-methyl-valyl-amiclenomycin (BA 2)IBA 01/2023 - 01/2022
4	Viral ProteinsIBA 01/2023 - 01/2010
4	Monoclonal AntibodiesIBA 02/2022 - 01/2011
4	Messenger RNA (mRNA)IBA 01/2022 - 09/2006
4	Poly I-CIBA 09/2020 - 03/2005
4	MicroRNAs (MicroRNA)IBA 01/2020 - 01/2016
4	ParaffinIBA 02/2015 - 08/2003
4	Combined VaccinesIBA 10/2010 - 01/2002
3	Glycoproteins (Glycoprotein)IBA 02/2024 - 01/2018
3	Biomarkers (Surrogate Marker)IBA 10/2021 - 01/2011
3	Interleukin-10 (Interleukin 10)IBA 01/2021 - 06/2008
3	Peptide Hydrolases (Proteases)FDA Link 01/2021 - 04/2006
3	DiamondIBA 01/2021 - 01/2020
3	Double-Stranded RNA (RNA, Double Stranded)IBA 09/2020 - 03/2005
3	NucleoproteinsIBA 09/2019 - 01/2012
3	Formaldehyde (Formol)FDA Link 03/2013 - 08/2003
2	Indicators and Reagents (Reagents)IBA 11/2023 - 05/2023
2	favipiravirIBA 07/2022 - 01/2016
2	peramivirIBA 07/2022 - 09/2020
2	molnupiravirIBA 02/2022 - 01/2022
2	nirmatrelvirIBA 02/2022 - 01/2022
2	COV2-2130IBA 02/2022 - 01/2022
2	COV2-2196IBA 02/2022 - 01/2022
2	EpitopesIBA 01/2022 - 01/2019
2	aluminum sulfate (alum)IBA 01/2022 - 01/2019
2	Amino Acids FDA Link 01/2021 - 06/2014
2	Poly IIBA 09/2020 - 09/2007
2	Viral AntigensIBA 01/2020 - 10/2019
2	GoldIBA 01/2020 - 05/2018
2	EnzymesIBA 01/2019 - 04/2018
2	Nucleocapsid ProteinsIBA 04/2018 - 04/2016
2	bu-zhong-yi-qi-tangIBA 01/2017 - 01/2013
2	InterleukinsIBA 08/2013 - 06/2008
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2013 - 06/2008
2	Interleukin-13IBA 08/2013 - 06/2008
2	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2013 - 11/2008
2	GTP-Binding Proteins (G-Protein)IBA 01/2013 - 01/2011
2	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2013 - 11/2008
2	poly(I).poly(c12,U) (ampligen)IBA 10/2009 - 09/2007
2	Toll-Like Receptor 3IBA 10/2009 - 09/2007
2	Smallpox Vaccine (Vaccine, Smallpox)FDA Link 03/2008 - 06/2006
2	ChitinIBA 06/2007 - 01/2005
2	Cytidine Monophosphate (CMP)IBA 10/2006 - 01/2005
1	LeptinIBA 01/2023
1	LigandsIBA 01/2023
1	Tissue Inhibitor of Metalloproteinase-1IBA 10/2022

Therapy/Procedure

8	Therapeutics 01/2023 - 04/2006
8	Intranasal Administration 11/2015 - 01/2002
2	Injections 07/2017 - 01/2017